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Abstract During an ST-elevation myocardial infarction (STEMI), the myocardium undergoes a prolonged period of ischaemia.
Reperfusion therapy is essential to minimize cardiac injury but can paradoxically cause further damage.
Experimental procedures to limit ischaemia and reperfusion (IR) injury have tended to focus on the cardiomyocytes
since they are crucial for cardiac function. However, there is increasing evidence that non-cardiomyocyte resident
cells in the heart (as discussed in a separate review in this Spotlight series) as well as circulating cells and factors
play important roles in this pathology. For example, erythrocytes, in addition to their main oxygen-ferrying role,
can protect the heart from IR injury via the export of nitric oxide bioactivity. Platelets are well-known to be in-
volved in haemostasis and thrombosis, but beyond these roles, they secrete numerous factors including
sphingosine-1 phosphate (S1P), platelet activating factor, and cytokines that can all strongly influence the develop-
ment of IR injury. This is particularly relevant given that most STEMI patients receive at least one type of platelet in-
hibitor. Moreover, there are large numbers of circulating vesicles in the blood, including microvesicles and exo-
somes, which can exert both beneficial and detrimental effects on IR injury. Some of these effects are mediated by
the transfer of microRNA (miRNA) to the heart. Synthetic miRNA molecules may offer an alternative approach to
limiting the response to IR injury. We discuss these and other circulating factors, focussing on potential therapeutic
targets relevant to IR injury. Given the prevalence of comorbidities such as diabetes in the target patient population,
their influence will also be discussed. This article is part of a Cardiovascular Research Spotlight Issue entitled
‘Cardioprotection Beyond the Cardiomyocyte’, and emerged as part of the discussions of the European Union
(EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action, CA16225.
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1. Introduction
During an ST-elevation myocardial infarction (STEMI) the myocardium
undergoes a prolonged period of ischaemia. Reperfusion therapy is es-
sential to minimize cardiac injury but can paradoxically cause further
damage.1 Experimental procedures to limit ischaemia and reperfusion
(IR) injury have been developed.1–3 These strategies include ischaemic
conditioning applied before ischaemia (preconditioning or IPC), after is-
chaemia (postconditioning or IPost), or to a distal organ or limb (remote
conditioning, RIC). In addition, numerous pharmacological strategies ac-
tivate either the PI3K/AKT (Reperfusion Injury Salvage Kinase, RISK),
JAK/STAT (survivor activating factor enhancement or SAFE), or cGMP/
PKG signalling pathways. These pathways have various effects on cardio-
myocytes, but inhibition of the mitochondrial permeability transition
pore (MPTP) has been described as a common end effector.1
Furthermore, the mechanism of cardioprotection may also involve
global changes in cardiac gene expression.4,5
Unfortunately, despite success in limiting IR injury in experimental ani-
mal models, the above approaches have not translated well to the clinical
setting.1,6 Possible reasons for this have been extensively discussed.1,2,6,7
One reason is likely to be the prevalence of comorbidities such as dysli-
pidaemia, diabetes, and age in the STEMI patient population, which can
impede cardioprotective strategies.8 Another reason is that many
patients are already taking drugs (e.g. statins) or are administered drugs
(e.g. platelet P2Y12 inhibitors) that are known to influence cardioprotec-
tion.8 It may also be relevant that, because of their crucial role in cardiac
function, most cardioprotection studies have focussed on protecting the
cardiomyocytes. However, increasing evidence suggests that solely tar-
geting cardiomyocytes may be insufficient to protect the heart in the
complex scenario of STEMI, and a multi-target approach may be neces-
sary.9 In this regard, it may also be important to consider the roles played
by innate immunity and inflammation, and the nervous system in addition
to non-cardiomyocyte cells resident in the heart—topics which are dis-
cussed in separate reviews in this Spotlight series.10–12 Here, we address
the importance of circulating blood cells and factors in IR injury and car-
dioprotection. We examine the role played by platelets, erythrocytes,
and the extracellular vesicles (EVs) they release into the blood. While
thrombosis is clearly a fundamental cause of coronary occlusion and
myocardial ischaemia, factors targeting the thrombus and clotting factors
may exert cardioprotective effects independent of occlusion.
Furthermore, non-vesicular ribonucleic acid (RNA) may be an important
cardioprotective approach. Lymphocytes play a complex role in IR in-
jury. Circulating B- and T-lymphocytes are recruited to the injured myo-
cardium in the days following infarction, and contribute to healing after
acute myocardial infarction (AMI), but there is also some evidence that T
cells contribute to acute myocardial IR injury. The role of lymphocytes
and other immune cells is discussed in detail in an accompanying review
in this series.11
While there are certainly roles for circulating cells and factors in the
longer time-scale of response to IR including inflammation and ventricu-
lar remodelling, we focus on their role in initial myocardial injury follow-
ing acute IR injury.
2. Platelets
Platelets are small, anucleate cell fragments whose primary function is to
initiate haemostasis in response to small vessel injury. However, they are
emerging as important factors in the regulation of vascular homeostasis
in many organs, including the heart. When activated, platelets can initiate
haemostasis to prevent bleeding and eventually propagate a thrombus.
STEMI is the consequence of coronary occlusion by thrombosis follow-
ing plaque rupture. The latter promotes platelet adhesion and aggrega-
tion, thereby contributes to the blood clotting process. Platelets release
various factors that may influence the heart during IR including cytokines,
microRNAs (miRNAs), chemerin, sphingosine-1-phosphate (S1P), and
platelet-activating factor (Figure 1), thereby affecting the non-
thrombogenic properties of the vascular endothelium and disturbing car-
diomyocyte functions.
Activated platelets release a variety of factors that can affect IR injury.
Some of these are vaso-active, as discussed further in an accompanying
review.13 Other factors may act directly on cardiomyocytes and worsen
their response to IR. For example, activated platelets release chemerin,
an adipokine involved in inflammation, obesity, insulin resistance, and
metabolic syndrome.14 Acting through chemokine-like receptor1
(CMKLR1 or ChemR23), it reduces AKT phosphorylation, activates
caspase-9, and induces apoptosis in murine cardiomyocytes, which sug-
gests it could also increase cardiac IR injury.15
Platelets also release numerous factors which may activate cardiopro-
tective RISK and SAFE pathways. For example, they are a major source
of CXCL12 (stromal cell derived factor-1a, SDF-1a), which is released
upon activation and can reduce IR injury in rodent and human myocar-
dium, in addition to promoting longer time-scale repair mechanisms.16,17
Platelet-derived S1P appears to make an important contribution to
protection from IR injury. Platelets contain sphingosine kinase, which can
transform membrane sphingosine into S1P for storage and release.18 S1P
can have both pro- and anti-aggregatory effects via G-protein coupled
receptors (GPCRs) on platelets.18 Importantly, S1P can also directly in-
duce myocardial protection, apparently via S1P1, S1P2, and S1P3 recep-
tors in cardiomyocytes, leading to activation of the RISK and SAFE
pathways.19–22 It has also been reported that PAK1/AKT/NOS3 signal-
ling may mediate cardioprotection by S1P.22,23 Mice lacking both S1P2
and S1P3 receptors have 50% smaller infarcts after IR,
22 but it is not clear
which cell type mediates this effect. Nevertheless, studies demonstrate
that S1P is a pivotal mediator of cardioprotection and can trigger IPC
and IPost. Indeed, S1P mediates powerful cardioprotection in isolated
mouse hearts.24,25
Diabetes can increase platelet hyperactivity and oxidative stress lead-
ing to cardiovascular complications.26 These alterations may, at least in
part, be responsible for the reduced ability to induce cardioprotection in
models of uncontrolled diabetes.8 Pre-treatment of isolated rat hearts
with platelets from healthy subjects was protective against IR injury,
whereas platelets from diabetic subjects were not, possibly due to al-
tered release of S1P.27
Cardioprotective strategies such as IPC and IPost can induce the re-
lease of S1P.25,26 Whether these manoeuvres affect S1P release from
platelets is not clear. Nevertheless, P2Y12 inhibitors induce a
conditioning-like cardioprotection that requires both platelets and
S1P.29–31 Platelets collected from patients with acute coronary syn-
drome (ACS) increased injury when perfused through isolated rat
hearts, and this cytotoxicity was blocked by P2Y12 inhibitors.
32
However, prevention of platelet aggregation alone is not protective
in vivo, since infarct size is unaltered in thrombocytopenic rats that re-
main untreated.31 All P2Y12 antagonists tested to date have been found
to be cardioprotective in animals, and neither IPC nor IPost can add pro-
tection to that induced by the anti-platelet drugs.29,33 Since virtually all
percutaneous coronary intervention (PCI) patients are treated with
P2Y12 inhibitors, it is important that future cardioprotective
Circulating cells and vesicles in cardioprotection 1157
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..interventions are tested in an animal model receiving a P2Y12 antagonist.
The failure to clinically translate IPost-mimetics, which had appeared so
protective in animal studies29,33 has led to the mistaken assumption that
animal hearts are not appropriate models of human hearts. But even in
animal studies, IPost was unable to confer further infarct size reduction
in an animal concomitantly treated with a P2Y12 antagonist.
29 It would
therefore appear that in the presence of a P2Y12 antagonist, further car-
dioprotection can be achieved only if the intervention has a different
mechanism of protection from the platelet inhibitor.19,29,33,34 This ap-
proach should pave the way to translation of cardioprotective protocols
into successful clinical treatments.
The phosphoglyceride platelet activating factor (PAF) is produced and
released by platelets, endothelial cells and leucocytes.35 PAF acts as an
autocrine/paracrine mediator on various cell types including cardiomyo-
cytes, endothelial cells, smooth muscle cells, and platelets.35 PAF has a
dual role in IR.35 IR causes the release of high quantities of PAF (1–
10 nmol/L) with direct and indirect negative effects on coronary and car-
diac functions, including a strong arrhythmogenic effect.35 At very low
concentrations (pM), PAF has a cardioprotective effect similar that that
elicited by IPC.35–37 Cardioprotection by PAF involves activation of the
RISK kinase pathway, including protein kinase C (PKC), AKT, and
NOS.36 Interestingly, a PAF-receptor antagonist impairs the infarct-
sparing effect of both IPC and PAF.36
Although PAF or other endogenous factors within platelets may par-
ticipate in triggering IPC-induced cardioprotection, they appear not to
be required for cardioprotection by IPC, since thrombocytopenia did
not abolish cardioprotection by IPC.19 However, platelets might still af-
fect infarction in patients with coronary artery disease or comorbidities
such as diabetes where platelets may be activated. Thus, platelets not
only affect haemostasis and thrombosis, but platelet-derived products in-
cluding EVs can have a profound effect on infarct size and
cardioprotection.
3. Erythrocytes
It is well-known that erythrocytes are involved in the regulation of the
cardiovascular system via mechanisms that include their interaction with
the endothelium.38–40 These mechanisms include the export of NO-like
bioactivity and ATP that exert important cardiovascular effects.
Additionally, erythropoietin, a kidney-derived cytokine that has the abil-
ity to increase red blood cell mass, can protect cardiomyocytes from ap-
optotic cell death through NOS3-derived NO production.41 In the
setting of IR, erythrocytes were originally suggested to protect the iso-
lated rat heart from IR injury via a NOS-dependent mechanism.42 This
was supported by the observation that mice with blood cells lacking
NOS3 had lower circulating nitrite and developed larger infarcts follow-
ing IR than control mice, supporting a role of erythrocyte NOS3 under
in vivo conditions.41,43 It was subsequently shown that export of NOS3-
derived NO bioactivity from erythrocytes induced cardioprotection in
the isolated heart.44 This effect was tightly controlled by the enzyme ar-
ginase which is known to reciprocally regulate NO formation by com-
peting with NOS3 for the substrate L-arginine. Consequently, inhibition
of erythrocyte arginase induces cardioprotection via a mechanism that is
entirely dependent on erythrocyte NOS3 (Figure 2).44
Interestingly, arginase is up-regulated in erythrocytes in type 2 diabe-
tes—an important comorbidity in patients with STEMI.45,46 Accordingly,
it was recently demonstrated that erythrocytes from both mice and
patients with type 2 diabetes markedly impair recovery of cardiac sys-
tolic function, increase left ventricular end-diastolic pressure and in-
crease infarct size following IR in comparison with erythrocytes from
control mice or healthy humans.46 The underlying mechanism behind
this effect was increased arginase activity in erythrocytes which led to a
decrease in NO production. It further resulted in increased reactive oxy-
gen species (ROS) production due to uncoupling of NOS3 and increased
expression of NADPH oxidase (NOX2) in erythrocytes.47 The ROS
species hydrogen peroxide produced by erythrocytes activates endothe-
lial cell arginase and NOX1, which results in endothelial oxidative stress
and impaired endothelium-dependent relaxation.47 Thus, available data
suggest that erythrocytes are prominently involved in events occurring
during IR by export of NO bioactivity under strict control of erythrocyte
arginase. Furthermore, erythrocytes are important targets for cardiopro-
tective therapies including arginase and ROS inhibition. In addition, eryth-
rocyte NOS/NO bioactivity has been suggested to be associated with
RIC via increased erythrocyte deformability.48 Finally, erythrocyte
Figure 1 Ischaemia and reperfusion causes the activation of platelets, which subsequently release a multitude of factors with divergent effects on infarct
size. These include exosomes and microvesicles (both types of extracellular vesicles), SDF-1a, chemerin, sphingosine-1 phosphate, and PAF. P2Y12 inhibitors
can prevent platelet activation and can also reduce infarct size (see text for details).
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dysfunction characterized by increased arginase activity and ROS pro-
duction leading to endothelial dysfunction aggravates IR injury and
increases infarct size in type 2 diabetes.46 Therefore, erythrocytes repre-
sent an important potential target for cardioprotection.
4. Extracellular vesicles and
circulating miRNA
In addition to circulating cells, blood contains large numbers of EVs.49–52
Most of these EVs originate from platelets and erythrocytes, but they are
also produced by other circulating cells such as leucocytes, and by vascu-
lar cells particularly the endothelium. Historically, the cardiovascular field
has focussed on the population of larger EVs, called microvesicles (MVs),
in part because they are relatively easy to study using methods such as
flow cytometry. Over the past few years, there has been increasing inter-
est in the smaller type of EVs called exosomes, particularly because of
their apparent signalling role.49–52 As we discuss, these different types of
EVs below, it is important to be aware that results can be highly depen-
dent on the isolation and purification methods used, and that the purity
and specific fractions of exosomes achieved using commonly used isola-
tion methods can be quite variable.50,52,53 Furthermore, while EVs cer-
tainly contain miRNA, miRNA is also found in the blood complexed to
lipoproteins and Argonaute proteins, and the relative importance of
these different vehicles for the transfer of miRNA is highly debated.
4.1 Exosomes
Exosomes are nano-sized (50–150 nm diameter) lipid bilayer vesicles re-
leased from cells when multivesicular bodies fuse with the plasma mem-
brane.50,52 Exosomes are secreted by all cell types and act as universal
propagators of intercellular communication. Since high concentrations
of exosomes are found in the blood (1010 per mL54), they have been
hypothesized to mediate the transmission of the cardioprotective signal
of RIC.55 Indeed, RIC was shown to increase the concentration of exo-
somes in the blood,54 and in 2014, the first evidence that cardioprotec-
tion by RIC might be transmitted by EVs, most likely exosomes, was
obtained.56 In this study, pre-treatment with exosomes from
conditioned donor hearts attenuated infarct size in non-preconditioned
recipient hearts undergoing IR.56 Recently, it has been shown that exo-
somes derived from the plasma of rats subjected to RIC play a role in re-
ducing oxidative stress-mediated injury.57
Platelets are a major source of circulating EVs, releasing both exo-
somes and MVs.52,58 Platelet EVs are also present in atherosclerotic pla-
ques.59 Several stimuli can augment the release of EVs, including
physical-chemical stresses and pro-apoptotic stimuli. Platelet exosomes
appear to have an anti-thrombotic effect.49 Platelet-derived EVs can
transfer RNAs to recipient cells and influence their activity.49,60 While
studies suggest an important role for platelet-derived miRNAs in haemo-
stasis, thrombosis, and unstable coronary syndromes,60 it is less clear
whether miRNA, either from platelets or EVs, could act rapidly enough
to influence acute infarct formation after IR.
Exosomes are increasingly being exploited for their therapeutic cardi-
oprotective role in progenitor/stem cell-based therapy.50 Molecules and
EVs secreted by progenitor cells appear to create a reparative and re-
generative milieu in the tissue microenvironment, which may be more
important than the differentiation potential of the cells themselves.
Exosomes purified from culture medium conditioned by resident cardiac
progenitor cells (Exo-CPC), but not exosomes released from normal
dermal fibroblasts, are cardioprotective and proangiogenic in vivo.61,62
Exo-CPC injected into the infarct border zone reduced scar size, in-
creased viable mass and vessel density, and improved global heart func-
tion after myocardial infarction (MI) in mice.61,62 Not only CPC-derived
exosomes can induce a cardioprotective signal, since differences are ob-
served when comparing CPC with exosomes from patient-matched,
bone-marrow derived, mesenchymal stem cell (BMC). Although Exo-
BMC provide some cardioprotection after AMI, they are not as effective
as Exo-CPC.63
The exact mechanism by which exosomes protect cardiomyocytes
from IR injury has yet to be elucidated but it may involve the exosome’s
cargo of mRNA, short non-coding RNA (miRNAs, Y-RNA) and/or pro-
teins.61,62,64 Given their abundance and specific expression within tissue-
specific exosomes, miRNAs appear to be an important component, al-
though there are some aspects that are not yet clear, including how
transferred miRNAs are incorporated into an endogenous RISC
Figure 2 Erythrocytes contain endothelial nitric oxide synthase (NOS3), which protects the heart via the production of nitric oxide (NO), S-nitrosothiols
(S-NO), or nitrite. Since NOS3 competes with arginase for the common substrate arginine, inhibition of arginase can be cardioprotective.
Circulating cells and vesicles in cardioprotection 1159
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complex and mediate their effect in competition with large amounts of
host miRNA.65 The most highly enriched miRNAs in Exo-CPC include
miR-146a-3p, miR-132, and miR-210.61,62 Gain and loss-of-function stud-
ies revealed antiapoptotic and proangiogenic properties of these
miRNAs. Plasma exosomes induced by RIC transfer miR-24 and de-
crease oxidative stress-mediated apoptosis into cardiomyocytes by
downregulating expression of the pro-apoptotic protein Bim.57
CPC cultured as 3-D cardiospheres (CDC) release exosomes that
contain many short RNAs that are unique to CDCs compared with fi-
broblast-derived exosomes.64 The most abundant RNA species found in
CDC-exosomes is a Y RNA fragment (EV-YF1).64 Its relative abundance
in CDC-exosomes correlates with an indirect in vivo reduction of cardio-
myocyte apoptosis, by increasing expression of the known cardioprotec-
tive cytokine interleukin 10 into macrophages within the ischaemic
area.64 CDCs-exosomes reduced infarct size 48 h after reperfusion
when injected in rats subjected to 45 min coronary artery occlusion.66 In
this case, cardioprotection was mediated by miR-181b, as demonstrated
by the loss of cardioprotection caused by miR-181b antagomir and by
the fact that inert exosomes from fibroblasts, after enrichment with
miR-181b, were able to reduce infarct size.66 Cardioprotection was
found to be related to the expression of the pro-inflammatory genes
NOS2 and TNF, protein kinase C d (PKCd), and increased macrophage
polarization.66
The protein cargo of plasma-derived exosomes includes heat-shock
protein 70 (HSP70), which plays a crucial role in pro-survival effects of
circulating exosomes when used in ex vivo, in vivo, and in vitro settings of
IR.54 Extracellular exosome-mediated signal activates ERK1/2 in cardio-
myocytes, which trigger toll-like receptor (TLR4) leading to phosphory-
lation of the cardioprotective protein HSP27.54 When any of these
proteins are selectively blocked, or HSP70 is absent from the surface of
exosomes, the cardioprotective signal is not propagated.54 Diabetes
impairs the cardioprotective activity of exosomes.67 However, exo-
somes from non-diabetic rats retained the ability to protect cardiomyo-
cytes from diabetic rats, indicating that exosome therapy can still be
effective despite the hyperglycaemic environment found in diabetic
patients.67 Among the most highly expressed protein on Exo-CPC is
pregnancy-associated plasma protein-A (PAPP-A), a protease that
releases active insulin growth factor 1, a key cardioprotective agent.
PAPP-A appears to be required for Exo-CPC to improve functional re-
covery after permanent coronary artery occlusion.63
Small animal studies suggest that exosomes could revolutionize medi-
cine due to their potent effects on cell behaviour including cardioprotec-
tion. However, there is a long route to the final goal of clinical benefits in
patients using exosome-based therapeutics.52 Little is known about what
is the most active fraction of collected samples for exosome studies.
Improved techniques for the isolation of defined size-ranges of exosome
populations are needed.52 It will also be important to develop methods
to target exosomes to the heart to limit their potential side effects on
other tissues. Finally, although some research groups have recently be-
gun to approach the technical challenge of isolating GMP (good labora-
tory procedures)-grade exosomes,68 several technical and regulatory
aspects will need to be overcome to enable the large-scale production
of exosomes.52 Furthermore, pre-clinical large animals studies will be
necessary before exosomes can be considered as a realistic therapeutic
approach for cardioprotection.
4.2 Microvesicles
MVs, also known as microparticles or ectosomes, are a heterogeneous
population of EVs formed by outward budding and/or shedding of the
plasma membrane. This process can occur in several cell types, including
endothelial cells, erythrocytes, leucocytes, platelets, and cardiomyo-
cytes.49,52 MVs are also heterogeneous in their size and molecular com-
position.49,52 Although initially considered plasma membrane fragments
emanating from platelets as part of the coagulation process,69 it is now
established that MVs are important players in intercellular communica-
tion, since they can convey proteins, lipids, nucleic acids, and other mole-
cules with biological activity such as cytokines, hormones, and
coagulation factors between distant cells.70 Circulating MVs have been
implicated in several physiological functions such as the coagulation pro-
cess, reticulocyte maturation, angiogenesis, tissue repair and inflamma-
tion.50,52,70 The concentration of MVs in the plasma is estimated to be
approximately 2–4  108 per mL.70 In healthy subjects, the majority are
of platelet origin as indicated by the presence of CD41, while the remain-
ing MVs derive from granulocytes, ECs, erythrocytes, and monocytes.70
In contrast to the beneficial effects of platelet exosomes, noted above,
platelet MVs can promote interactions between platelets, endothelial
cells, and monocytes favouring atherogenesis.49,51,70,71 Since MVs con-
tain procoagulant platelet membrane components, they can potentiate
the coagulation response.49
The number of circulating MVs increases in patients with heart failure
and vascular inflammation, most likely due to platelet activation.49,52
Moreover, the number of circulating procoagulant MVs is elevated in
patients with ACS and chronic ischaemic heart disease.52 Endothelial-
derived MVs can increase in heart failure, hypertension, coronary artery
disease, and carotid artery disease, possibly due to endothelial injury and
dysfunction.72
In addition to their importance as biomarkers, MVs elicit biological
responses in recipient cells which may depend on the cell-type and of or-
igin as well as its physiological status.52 For example, platelet-derived
MVs injected into the myocardium induced angiogenesis and stimulated
post-ischaemic revascularization in a rat model of MI.73 IPC increased
the number of circulating MVs derived from platelets, endothelial cells
and erythrocytes, and administration of these MVs significantly alleviated
damage to the myocardium and restored cardiac function after IR injury
by inhibiting endoplasmic reticulum stress.74 MVs from mesenchymal
stem cells overexpressing GATA-4 were found to be cardioprotective,
and this was attributed to an increase in miR-221 levels in the MVs, which
were taken up by cardiomyocytes and silenced the pro-apoptotic pro-
tein PUMA.75
On the other hand, IR may cause the release of MVs that are more
damaging. MVs released from endothelial cells after IR were pro-
apoptotic and pro-oxidative to cardiomyocytes.76 Furthermore, MVs
originating from cardiomyocytes and endothelial cells following AMI can
also be internalized by infiltrating monocytes and regulate local inflam-
matory responses.77
4.3 Non-vesicular non-coding RNAs
The majority (98%) of RNA molecules in the body are non-coding RNA
molecules.78,79 These include ribosomal RNA, transfer RNA,
microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular
RNAs (circRNAs).78 miRNAs are single-stranded RNA molecules, 21–
23 nucleotides in length that affect gene expression by binding to particu-
lar mRNAs and promote their degradation or inhibiting their translation
into proteins. LncRNAs and circRNAs regulate the expression of genes
via a complex array of epigenetic, post-transcriptional, and translational
modes. The effects of miRNAs are sequence-specific, but each miRNA
can affect numerous mRNA molecules and each mRNA can be affected
by numerous miRNAs. Since non-coding RNA molecules are involved in
1160 S.M. Davidson et al.
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‘fine tuning’ of the expression of proteins in numerous signalling pro-
cesses in the body, there is great interest in developing approaches to
administer them systemically as therapeutic agents.
The miR-15 family was reported to be detrimental in IR.80 In this
study, a locked nucleic acid-modified (LNA)-anti-miR complementary to
the seed region of the miR-15 family (LNA-miR-15), administered intra-
venously at the onset of reperfusion, limited infarct size in mice subjected
to 75 min ischaemia followed by 24 h reperfusion.80 Targeting miR-15
also prevented the decrease in Pdk4 (a key regulator of mitochondrial
function) and Sgk1 (an inhibitor of cardiomyocyte apoptosis).80
In pigs subject to 60 min ischaemia followed by reperfusion, adminis-
tration of LNA-miR-92a 5 min prior to reperfusion reduced infarct size
and left ventricular function improved.81 However, a benefit was only
seen after catheter-based delivery, and not by intravenous infusion.
LNA-92a also increased capillary density and decreased leucocyte infil-
tration and cardiomyocyte cell death.81
In rabbits, intravenous administration of liposomal-encapsulated miR-
145 immediately after reperfusion (following 30 min coronary artery oc-
clusion) reduced myocardial infarct size and improved left ventricular
function 2 weeks after infarction.82 The target of miR-145 was found to
be fibroblast growth factor receptor substrate 2, and its effect was at
least partially mediated by the activation of autophagy.82
Following physical or pharmacological interventions, changes in the
expression of certain non-coding RNAs might be expected to reveal
those that represent the most promising targets. Several studies have ex-
plored which non-coding RNAs are affected by IR or interventions such
as IPC and IPost and have tested whether these non-coding RNAs have
protective effects in experimental models.4
Using unbiased miRNA omics approach, several miRNAs were identi-
fied that affected by IPC and IPost and termed these miRNAs
protectomiRs. Transfection of protectomiRs (specific miRNA mimics or
antagomirs as appropriate) into cardiac myocytes validated their cardio-
cytoprotective efficacy. In particular, a miR-125b* mimic was shown to
be of high relevance for cardioprotection.83,84 As expected, the concen-
tration of numerous non-coding RNA molecules is altered by ischaemia,
IR, conditioning stimuli and medications. Several group have shown that
by offsetting these changes with specific agonists or antagonist, the pro-
tective effects of various interventions are lost. For example, inhibiting
miR-499 abolishes the protective effect of post-conditioning85; the pro-
tective effect of pioglitazone in vitro against simulated IR is dependent on
downregulating miR-29 levels. Hence, 3-day pre-treatment with antago-
mirs against miR-29a or 29c attenuated apoptosis and limited infarct size
in an in vivo rat model of 30 min ischaemia/24 h reperfusion.86
Another example of a cardioprotective miRNA is miR-21. In an iso-
lated heart model, infarct size was smaller when mice had been pre-
treated 24 h previously with synthetic miR-21.87 However, miR-21 also
appears to contribute to remodelling and fibrosis in the failing heart.88
Although this review focusses primarily on studies in which non-cod-
ing RNAs or their antagonists was administered around the time of re-
perfusion because of their relevance to patients with STEMI, it should be
noted that benefit for RNA-based therapies has also been seen in mod-
els of permanent coronary artery ligation and/or when treatment is ad-
ministered prior to the onset of ischaemia.79
In general, the use of non-coding RNA based-therapy as a short-term
therapy to mitigate IR injury and reduce infarct size in patients presenting
with STEMI requires rapid and specific delivery of the RNA molecules to
the heart, and a rapid onset of action.4 In the clinical setting such thera-
peutic agents should either be given intravenously during the ischaemic
phase or intravenously or intra-coronary during primary PCI, and must
be able to enter the cells rapidly and have a rapid effect gene expression.
Approaches are being developed to aid intracellular RNA delivery or
chemically modify RNA to permit its direct cellular uptake.89,90
However, clinical translation of these pharmaceutical agents is still at an
early stage.
5. Thrombosis and blood clotting
factors
Several interventions targeting blood clotting factors have been found to
limit infarct size independently of the haemostatic function of these pro-
teins. Blood coagulation is initiated when plasma factor VII (FVII) binds to
its cellular receptor tissue factor (TF), (expressed on deeper cell layers
of the vessel wall), and is converted to the active protease FVIIa (extrin-
sic initiation pathway) (Figure 3).91 The TF:FVIIa complex activates the
factors IX and X resulting in the generation of only minute amounts of
thrombin that immediately start to amplify its own production by activat-
ing factors XI, VIII, and V. These reactions of the intrinsic pathway result
in the mass production of thrombin, now available to induce fibrin for-
mation and blood clotting. Additionally, thrombin activates platelets, en-
dothelial cells, and cardiomyocytes, by cleavage of protease activated
receptors (PARs) and the subsequent activation of intracellular signalling
pathways.92 The intrinsic regulation of blood coagulation is achieved by
the thrombin-induced generation of the thrombomodulin-protein C
pathway, resulting in an effective control of thrombin generation.
TF initiates the clotting cascade and is a major prothrombotic factor.93
Increased plasma TF levels, associated with EVs, are observed in patients
with AMI, reflecting enhanced intravascular procoagulant activity.93
Experimental studies indicate that cardiac IR increases TF activity. In vivo
studies in rabbit models have shown that anti-TF therapy prevented the
transient decrease in regional myocardial blood flow, reduced platelet
and fibrin(ogen) accumulation, and reduced infarct size.94 Thrombin may
also contribute to the pathology of IR injury, since in a rabbit model of
IR, selective inhibition of thrombin by recombinant hirudin (lepirudin)
decreased infarct size.94 The TF-thrombin pathway may also contribute
to myocardial injury by an additional mechanism that is not dependent
on fibrin deposition but involves activation of PARs on vascular endothe-
lial cells and cardiac myocytes.94 Since myocardial IR injury is partly medi-
ated by thrombin and several cellular responses to thrombin are
mediated by PARs, PARs have been extensively investigated as potential
targets for cardioprotection.
The four known PARs are GPCRs that are activated by several serine
proteases, including coagulation and mast cell-derived proteases. For ex-
ample, thrombin cleaves and activates PAR-1, -3, and -4 on a variety of
cells and thereby activates each of these receptors, whose new amino-
terminal portion serves as leached ligand.95 PAR-1 is the high-affinity re-
ceptor for thrombin and is expressed by several cell types in the heart,
including cardiomyocytes and cardiac fibroblasts. Since PAR-1 is
expressed as a ‘cell-bound substrate’ of thrombin on both platelets and
immune cells, hormonal doses of the enzyme are sufficient to provoke
platelet aggregation or a variety of immune responses in the context of
inflammation and cardiovascular disease.96 Treatment of rats or isolated
hearts with a selective PAR-1 antagonist, reduced infarct size in a dose-
dependent manner and increased ventricular recovery following IR.97
When PAR-1 is cleaved by thrombin it releases a 41-amino-acid peptide
called parstatin. Both parstatin and its putative signal peptide (N-terminal
fragment 1-26), reduced infarct size when administered to rats prior to
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..IR.98,99 The underlying mechanisms may involve the known cardiopro-
tective pathways including the RISK and the MPTP pathway.99
Activated protein C (APC) is a serine protease that serves as natural
anticoagulant with an important role in regulating thrombin formation
and the extent of fibrin formation. It is recognized by the endothelial pro-
tein C receptor and alters signalling of the thrombin-PAR-1 complex. In
a mouse model of acute IRI, administration of APC significantly reduced
myocardial infarct size,100–102 with PAR-1 required for this process.101
Interestingly, a variant APC, lacking catalytic activity, remained protec-
tive, implying that the protection from IRI is independent of its proteo-
lytic activity.100 Furthermore, infarct size reduction depended on its
PAR-1 signalling, but not its anticoagulant properties.102
Although APC serves as a major ligand/activator of PAR-2 on immune
cells, its role in IRI is controversially discussed and the protease(s) that
activate PAR-2 during cardiac IRI are not known.94 Infarct size was signifi-
cantly reduced in PAR-2-/- mice subjected to 30 min ischaemia and 2 h
Figure 3 Initiation, amplification and feedback anticoagulant mechanisms in the coagulation cascade. The different phases, from initiation of coagulation
due to exposure of tissue factor and binding of its ligand factor VII/VIIa either at a wound/extravascular site or in the intravascular compartment (microve-
sicles), designated as ‘extrinsic pathway’, to amplification and production of thrombin by the positive feedback reactions of the ‘intrinsic pathway’ are indi-
cated. In parallel to fibrin clot formation, the majority of thrombin will distantly bind to its endothelial cell receptor thrombomodulin to induce the activation
of protein C (PC) into APC, which limits further thrombin production by degrading the procoagulant cofactors VIIIa and Va. While these reactions are suffi-
cient to achieve wound healing upon physiological haemostasis, when an atherosclerotic plaque ruptures, thrombogenic substrates are exposed that can ini-
tiate (auto-) activation of the factor XII-dependent reactions of the contact phase, resulting in enhanced thrombin generation and hence, fibrin clot
formation and eventually thrombosis. The inhibitors mentioned in the text are indicated in red.
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.reperfusion, as well as exhibiting decreasing oxidative/nitrative stress.103
In contrast, infusion of a PAR-2-activating peptide reduced infarct size in
isolated perfused rat hearts.104 Interestingly, this peptide showed addi-
tive protection with an IPC protocol of 2 min ischaemia followed by
10 min reperfusion.105 Furthermore, the PAR-2 agonist peptide SLIGRL
reduced infarct size when administered to rats at the time of reperfusion,
via a pathway involving ERK1/2 and PKC.106 SLIGRL also reduced infarct
size in isolated rats hearts, via pathways involving PKCe or PKA, and tran-
sient receptor potential vanilloid type 1 -dependent release of calcitonin
gene-related peptide and substance P.107
PAR-4 knockout mice exhibited reduced infarct size after acute IR.
This may be due to protection from a Src- and epidermal growth factor
receptor-dependent pathway of JNK-induced apoptosis.108 Two struc-
turally unrelated PAR-4 antagonists reduced infarct size in rats when ad-
ministered prior to ischaemia either in vitro or in vivo, via a mechanism
that appears to involve adenosine.109
Plasmin is the main enzyme that dissolves fibrin blood clots. The main
function of plasminogen activator inhibitor type-1 (PAI-1 or SERPIN E1)
is to oppose the plasmin activation cascade, thereby maintaining the clot.
Increased expression of PAI-1 is profibrotic in hearts subjected to MI.
A markedly greater extent of infarction was observed in PAI-1 knockout
mice compared with controls and this was associated with haemorrhage
and inflammation.110
Overall, pharmaceutical agents targeting thrombosis and blood clot-
ting factors appear have multiple benefits in the setting of IR, including
benefits independent of haemostasis, although these are not always easy
to completely separate mechanistically.
6. Conclusion
As can be seen from this review, circulating cells and factors can strongly
impact IR injury via various mechanisms. Erythrocytes, for example, can
export NO bioactivity and be cardioprotective. Platelets, in addition to
their role in haemostasis and thrombosis, secrete a large number of fac-
tors that can influence the development of IR injury both positively and
negatively. Erythrocytes, platelets, and other cell types can release both
MVs and exosomes which may have both detrimental or protective
characteristics in the setting of IR. These effects may be mediated by the
transfer of miRNA to cardiomyocytes, or through ligand-receptor signal-
ling or other mediators (e.g. NO).
In many of the experiments described, the end target is likely to be
the cardiomyocyte, since ultimately, it is these cells that must be pre-
served in order to limit infarct size and retain contractile function.
However, there are other important aspects to IR injury such as endo-
thelial damage and microvascular obstruction which may be targets.
Furthermore, the interactions between thrombus, clotting factors and
circulating haematopoietic cells have not yet been clarified in terms of IR
injury. With greater understanding of PAR-1 and PAR-4 signalling path-
ways and their role in IR injury may come opportunities for better tai-
lored therapies to prevent tissue injury.
One firm conclusion that can be drawn is that it is important to con-
sider the interaction of potential cardioprotective agents with comedica-
tions such as platelet inhibitors, since these appear to have
cardioprotective actions independent of their role in haemostasis.
Furthermore, comorbidities such as diabetes can impact not only the in-
duction of cardioprotection in the target cardiomyocytes, but can also
influence the function of platelets, erythrocytes and EVs, and
consequently impair their ability to mediate cardioprotection. Finally, fu-
ture studies of potential cardioprotective agents should consider not just
their direct effect on cardiomyocytes, but on indirect effects that may be
mediated via circulating blood cells and factors.
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